Symbol="IMTX"
AssetType="Common Stock"
Name="Immatics NV"
Description="Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany."
CIK="1809196"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="PAUL EHRLICH-STRASSE 15, TUBINGEN, DE"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="998368000"
EBITDA="-61604000"
PERatio="None"
PEGRatio="None"
BookValue="2.61"
DividendPerShare="0"
DividendYield="0"
EPS="-1.19"
RevenuePerShareTTM="1.128"
ProfitMargin="-0.852"
OperatingMarginTTM="-0.815"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.43"
RevenueTTM="79720000"
GrossProfitTTM="172831000"
DilutedEPSTTM="-1.19"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.905"
AnalystTargetPrice="18.22"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.703"
PriceToBookRatio="6.18"
EVToRevenue="2.833"
EVToEBITDA="9.92"
Beta="0.501"
num_52WeekHigh="13.6"
num_52WeekLow="5.9"
num_50DayMovingAverage="11.82"
num_200DayMovingAverage="9.56"
SharesOutstanding="76672000"
DividendDate="None"
ExDividendDate="None"
symbol="IMTX"
open="12.30"
high="12.58"
low="12.13"
price="12.46"
volume="284118.00"
latest_trading_day="2023-08-21"
previous_close="12.21"
change="0.25"
change_percent="2.0475%"
aroon_positive_momentum_days="77"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="77"
Volume_recent_avg="446046"
Change_recent_avg="0.02"
Delta_recent_avg="0.58"
Variance_recent_avg="0.29"
Change_ratio_recent_avg="0.04"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="77"
Aroon_momentum_negative="23"
image_negative_thumbnail_id_1="491"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0114.jpeg"
image_negative_thumbnail_id_2="1105"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0138.jpeg"
image_neutral_thumbnail_id_1="589"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_neutral_thumbnail_id_2="537"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_positive_thumbnail_id_1="621"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0087.jpeg"
image_positive_thumbnail_id_2="950"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0112.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
